Pfizer Reaffirms FY 2026 Outlook Amid Leadership Change
Pfizer reaffirmed its full-year 2026 financial outlook despite a leadership change in the CFO role, with Dave Denton stepping down and Cecile Guegan taking over as interim CFO. The company maintains revenue guidance of $59.5 billion to $62.5 billion and adjusted diluted earnings per share between $2.80 and $3.
Tickers: $PFE